



## **Issue of Shares**

NEW YORK and SYDNEY, Australia, 6 June, 2025 - Beroni Group (OTCQB: BNIGF; NSX: BTG) ("Beroni" or the "Company"), advises that the Company has issued 5,010,000 ordinary shares to directors, employees and scientists as incentive shares, following shareholder approval received on 30 May 2025. The new shares are subject to a 12 month holding lock from the date of issue. The holding lock will be released on expiry of the 12 month period or the lodgement of a cleansing prospectus.

-End-

### **About Beroni Group Limited**

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit [www.beronigroup.com](http://www.beronigroup.com).

For more information, please contact us at:

Tel: +61 2 9159 1827

Email: [enquiry@beronigroup.com](mailto:enquiry@beronigroup.com)

Website: [www.beronigroup.com](http://www.beronigroup.com)